Home › Myotonic Dystrophy › New York › Rochester
Myotonic Dystrophy clinical trials in Rochester, NY
7 studies for Myotonic Dystrophy are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
RecruitingPhase 3
- University of Rochester Medical Center, Rochester
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
RecruitingObservational study
- University of Rochester, Rochester
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
RecruitingObservational study
- University of Rochester Medical Center, Rochester
Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
RecruitingObservational study
- University of Rochester, Rochester
Remote Assessments and Genetic Determinants of Myotonic Dystrophy
RecruitingObservational study
- University of Rochester, Rochester
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RecruitingObservational studyHealthy volunteers welcome
- University of Rochester Medical Center, Department of Neurology, Rochester
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
RecruitingPhase 2/3
- University of Rochester - Medical Center, Rochester
Myotonic Dystrophy trials in other cities
- Richmond, VA8 studies
- Boston, MA4 studies
- Los Angeles, CA4 studies
- Gainesville, FL3 studies
- Cedar Rapids, IA3 studies
Other studies in Rochester
- Acute Myeloid Leukemia16 studies
- Cancer (all types)15 studies
- Breast Cancer15 studies
- Lung Cancer15 studies
- Obesity14 studies
- Overweight13 studies
- Non-Small Cell Lung Cancer13 studies
- Prostate Cancer10 studies
- Metastatic Cancer8 studies
- Multiple Myeloma8 studies
- Pancreatic Cancer7 studies
- Bladder Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.